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1 INTRODUCTION  
The drugs are most often administered by oral route, but 
approximately 40% of new drug candidates have 
poor‐water solubility and the oral delivery of such drugs 
is difficult because of Their low bioavailability, high 
intra‐ and inter‐subject variability, and a lack of dose 
proportionality.
1
 To overcome these problems, various 
strategies are exploited including the use of surfactants, 
lipids, permeation enhancers, micronization, salt 
formation, cyclodextrins, 
nanoparticles and solid dispersions .BCS Class II drugs 
suffer from poor water solubility and high lipophilicity 
resulting in a highly variable oral bioavailability of 
formulations. They contain potential pharmacodynamic 
activity they fail to reach in the market. Bioavailability 
of Class II drugs is rate limited by its dissolution profile . 
So a increase in its dissolution rate results in a large 
increase in bioavailability. The solubility of the drug 
could be increased in three ways: changing the chemical 
structure in the lead optimization phase; prodrug 
approach and the formulation approach. Formulation 
strategies such as micronization, co-solubulization, solid 
dispersion, inclusion complex, nanosuspension, lipid 
based formulations etc., may be employed to enhance 
their dissolution, thereby their bioavailability.
2-6 
BCS class  Problems 
Class I  Enzymatic degradation, gut wall efflux 
Class II  Solubilization and bioavailability 
Class III  Enzymatic degradation, gut wall efflux 
and bioavailability 
Class IV  Solubilization, Enzymatic degradation, 
gut wall efflux and bioavailability 
 
Figure 1: Biopharmaceutics classification system 
Figure 1 indicating that absorption of a class II drug can 
be markedly improved by attention to the formulation. 
Formulation may improve the bioavailability of class IV 
drugs but they are likely to be compromised by their 
poor membrane permeability. If a class II drug can be 
maintained in a solubilized state in the lumen of the gut 
one can achieve an absorption profile more like that of a 
class I drug. Formulation strategies can do little to 
improve the absorption of classes I and III drugs which 
are limited by poor membranepermeability.
7
 
Self emulsifying drug delivery systems (SEDDS) also 
called as self emulsifying oil formulation which is 
mixture of oils and surfactants, ideally isotropic, and 
sometimes containing co-solvants, which emulsify 
spontaneously to produce fine oil in water emulsion 
when introduced into aqueous phase under gentle 
agitation. Self nanoemulsifying (SNEDDS), self 
microemulsifying (SMEDDS) and self-emulsifying drug 
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delivery systems (SEDDS) to improve the oral 
bioavailability of poorly water- soluble drugs .Self nano-
emulsifying drug delivery systems. These systems have a 
unique property, they are able to self-emulsify rapidly in 
gastro-intestinal fluids and under the gentle agitation 
provided by the motion of the gastro- intestinal tract and 
they form fine O/W emulsions.
8
 These fine O/W 
emulsions produce small droplets of oil dispersed in  the 
gastro -intestinal fluids that provide large interfacial area 
increasing the activity of pancreatic lipase to hydrolyze 
triglycerides and, thereby, promote a faster release of the 
drug and/or formation of mixed micelles of the bile salts 
containing the drug. Furthermore, in most cases the 
surfactant used for such formulations increases the 
bioavailability of the drug by activation of different 
mechanisms, maintaining the drug in solution and, thus, 
avoiding the dissolution step from the crystalline state 
and enhancing intestinal epithelial permeability at the 
same time. Moreover, the oil droplets lead to a faster and 
more uniform distribution of the drug in the 
gastrointestinal tract, minimizing the irritation due to 
contact between the drug and the gut wall. In addition, 
lipids affect the oral bioavailability of drugs by exerting 
their effect through several mechanisms, including 
protection of the drug from enzymatic or chemical 
degradation in the oil droplets and activation of 
lipoproteins promoting the lymphatic transport of 
lipophilic drugs.
9
 These systems may then be 
incorporated into capsules directly, or transformed into 
granules, pellets, and powders for dry filled capsules as 
well as tablet preparations. Various formulation 
techniques have been developed to improve the 
bioavailability of poorly water-soluble drugs,  such as 
solid dispersion, cyclodextrins, emulsions, liposomes, 
and nanoparticles.
10
 Among these methods, much 
attention has  recently been focused on self-
nanoemulsifying drug delivery  systems (SNEDDSs) to 
improve the oral bioavailability of  poorly soluble 
drugs.
11–15
 For SNEDDSs, isotropic mixtures  of oils and 
surfactants are used to form fine oil-in-water  
nanoemulsions when exposed to aqueous media, such as  
gastrointestinal fluids under mild agitation with droplet 
size less than 200 nm.The latter option is possible by 
innovative adaptations of conventional equipment  with 
relative ease and process simplicity, using methods like 
melt granulation, adsorption on a  solid support, spray 
drying, spray cooling, melt-extrusion/spheronization, and 
supercritical fluid  based methods.
16
 
 
 
 
 
1.2 Potential advantages of these systems include
17-19
 
 Enhanced oral bioavailability enabling reduction in 
dose.  
  More consistent temporal profiles of drug 
absorption.  
 Selective targeting of drug(s) toward specific 
absorption window in GIT  
 Protection of drug(s) from the hostile environment 
in gut.  
  Control of delivery profiles.  
  Reduced variability including food effects.  
  Protection of sensitive drug substances.  
  High drug payloads.  
 Quick onset of action.  
 Ease of manufacture and scale up. 
 
1.3 Factors affecting SNEDDS
20
 
 Drugs which are administered at very high dose are 
not suitable for SNEDDS 
 The drugs exhibit limited solubility in water and 
lipids are most difficult to deliver by SNEDDS. 
 The ability of SNEDDS to maintain the drug in 
solubilized form is greatly influenced by the 
solubility of the drug in oily phase. 
 If the surfactant or co-surfactant is contributing to a 
greater extent for drug solubilization, thenthere 
could be a risk of precipitation. 
1.4 Composition of SEDDs: 
21-23
 
The SEDDs is mainly composed of the following: 
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Drugs: 
Generally, SEDDs are prepared for drugs possessing 
poor water-solubility. BCS class II drugs are usually 
employed in preparation of SEDDs. Examples include 
itraconazole, nifedipine, vitamin E, simvastatin, danazol, 
ketoconazole, mefanimicacid, carbamazepine, 
glibenclamide, cyclosporine-A, ritonavir  etc.( Table 1) 
Table 1: Type of drugs used with surfactants in 
SEDDs 
Surfactant Drug 
PEG-35 Ibuprofen 
Tween 80 Cyclosporine-A 
Cremophore RH 40 Furosemide 
Cremophore EL Glibenclamide 
 
Surfactant:  
Numerous compounds exhibiting surfactant properties 
might to the design of self-emulsifying systems, but the 
choice is limited at the same time as very few surfactants 
are orally suitable, because safety is a major determining 
factor in choosing a surfactant. Emulsifiers of natural 
origin are preferred since they are considered to be safer 
than the synthetic surfactant. The most extensively 
suggested ones being the non-ionic surfactants with a 
relatively highhydrophilic lipophilic balance (HLB). To 
form stable SEDDs, 30-60% concentration of surfactant 
is used .
24
 Table (2) 
The four main groups of surfactants are - 
1)Anionic surfactants:  Potassium laurate, sodium 
lauryl sulphate. 
2) Cationic surfactant :Quaternary ammonium halide. 
3) Ampholytic surfactants: Sulfobetaines. 
4) Nonionic surfactants:Sorbitan esters (Spans), poly –
sorbates(Tweens). 
 
Table 2: Type of surfactants used in marketed SEDDs: 
Surfactant Marketed drug product Drug 
Cremophor RH 40 Neural soft gelatin capsule Cyclosporine A 
Span 20 Kaletra tablet, soft gelatin capsule Lopinavir 
Polysorbate 80 Lipofen hard gelatin capsule Fenofibrate 
Gelucire 44 Targretin soft gelatin capsule Bexarotene 
 
Oils:  
Long chain triglyceride and medium chain triglyceride 
oils with different degree of saturation have been used in 
the design of SEDDs. Unmodified edible oils provide the 
most natural basis for lipid vehicles, but their poor ability 
to dissolve large amounts of hydrophobic drugs and their 
relative difficulty in efficient self emulsification 
markedly reduces their use in SEDDs. Recently medium 
chain triglycerides are replaced by novel semi synthetic 
medium chain triglycerides containing compound such 
as GELUCIRE. other suitable oil phases are and fats 
which are used normally such as olive oil, corn oil, soya 
bean oil, and animal fats .
25
( Table 3) 
Table 3: Type of oil used with drug in SEDDs 
Oil Drug 
Palm kernel oi Ibuprofen 
Castor oil Cyclosporin-A 
Captex 500 Furosemide 
Capmul MCM C8 Glibenclamide 
Lemon oil Diclofenac Sodium 
 
Co-solvents:  
Usually an effective self emulsifying formulation 
requires a high concentration of surfactant. Accordingly, 
co - solvents such as ethanol, propylene glycol and 
polyethylene glycol are required to facilitate the 
dissolution of large quantities of hydrophilic surfactant. 
These co -solvents sometimes play the role of the co- 
surfactant in the micro- emulsion system. On the other 
hand, alcohol and other volatile co-solvents have the 
drawback of evaporating into the shell of soft or hard 
gelatin capsules, leading to precipitation of the drug. 
Polymers: 
Inert polymer matrix representing from 5 to 40% of 
composition relative to the weight, which is not ionizable 
at physiological pH and being capable of forming matrix 
are  used. 
Examples - hydroxyl propyl methyl cellulose, ethyl 
cellulose, etc. 
2 MECHANISM OF SELF EMULSIFICATION:
26
 
Self emulsification occurs when the entropy change that 
favors dispersion is greater than the energy required to 
increase the surface area of the dispersion .The free 
energy of the conventional emulsion is a direct function 
of the energy required to create a new surface  between 
the oil and water phase and can be described by the 
equation 1. 
DG = SNpr 2s……(1) 
Where  
DG  =free energy associated with the process . 
N = number of droplets  
r = radius of droplets . 
s = interfacial energy. 
The two phase of  emulsion  tend to separate with time to 
reduce  the  interfacial  area  and subsequently  the 
emulsion is stabilized  by emulsifying agent ,which form 
Gautam et al                                      Journal of Drug Delivery & Therapeutics. 2014; 4(6):33-38 36 
© 2011-14, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                              CODEN (USA): JDDTAO 
a monolayer of emulsion droplets and hence reduce the 
interfacial energy as well as providing a barrier to 
prevent  coalescence. 
 
Figure 2: Formulation of SNEDDS 
3. EVALUATION: 
3.1 Thermodynamic stability studies
27
 
The physical stability of a lipid –based formulation is 
also crucial to its performance, which can be adversely 
affected by precipitation of the drug in the excipient 
matrix. In addition, poor formulation physical stability 
can lead to phase separation of the excipient, affecting 
not only formulation performance, but visual appearance 
as well. In addition, incompatibilities between the 
formulation and the gelatin capsules shell can lead to 
brittleness or deformation, delayed disintegration, or 
incomplete release of drug. 
1. Heating cooling cycle: Six cycles between refrigerator 
temperature (40C) and 450C with storage at each 
temperature of not less than 48 h is studied. Those 
formulations, which are stable at these temperatures, are 
subjected to centrifugation test. 
2. Centrifugation: Passed formulations are centrifuged 
thaw cycles between 21 0C and +25 0C with storage at 
each temperature for not less than 48 h is done at 
3500rpm for 30 min. Those formulations that do not 
show any phase separation are taken for the freeze thaw 
stress test. 
3. Freeze thaw cycle: Three freeze for the formulations. 
Those formulations passed this test showed good 
stability with no phase separation, creaming, or cracking.  
3.2 Dispersibility test
28
 
The efficiency of self-emulsification of oral nano or 
microemulsion is assessed using a standard USP XXII 
dissolution apparatus 2. One milliliter of each 
formulation was added to 500 mL of water at 37 ± 0.5 
0C. A standard stainless steel dissolution paddle rotating 
at 50 rpm provided gentle agitation. The in vitro 
performance of the formulations is visually assessed 
using the following grading system: 
Grade A: Rapidly forming (within 1 min) nanoemulsion, 
having a clear or bluish appearance. 
Grade B: Rapidly forming, slightly less clear emulsion, 
having a bluish white appearance. 
Grade C: Fine milky emulsion that formed within 2 min. 
Grade D: Dull, grayish white emulsion having slightly 
oily appearance that is slow to emulsify (longer than 
2min). 
Grade E: Formulation, exhibiting either poor or minimal 
emulsification with large oil globules present on the 
surface. 
Grade A and Grade B formulation will remain as 
nanoemulsion when dispersed in GIT. While formulation 
falling in Grade C could be recommend for SEDDS 
formulation.  
3.3 Turbidimetric Evaluation
27
 
Nepheloturbidimetric evaluation is done to monitor the 
growth of emulsification. Fixed quantity of Self 
emulsifying system is added to fixed quantity of suitable 
medium (0.1N hydrochloric acid) under continuous 
stirring (50 rpm) on magnetic plate at ambient 
temperature, and the increase in turbidity is measured 
using a turbid-meter. However, since the time required 
for complete emulsification is too short, it is not possible 
to monitor the rate of change of turbidity (rate of 
emulsification) 
3.4 Viscosity Determination 
The SEDDS system is generally administered in soft 
gelatin or hard gelatin capsules. so, it can be easily 
pourable into capsules and such system should not too 
thick to create a problem. The rheological properties of 
the micro emulsion are evaluated by Brookfield 
viscometer. This viscosities determination conform 
whether the system is w/o or o/w. If system has low 
viscosity then it is o/w type of the system and if high 
viscosities then it are w/o type of the system. 
3.5 Droplet Size Analysis Particle Size 
Measurements
27
 
The droplet size of the emulsions is determined by 
photoncorrelation spectroscopy (which analyses the 
fluctuationsin light scattering due to Brownian motion of 
the particles) using a Zetasizer able to measure sizes 
between10 and 5000 nm. Light scattering is monitored at 
25°C ata 90° angle, after external standardization with 
sphericalpolystyrene beads. The nanometric size range of 
theparticle is retained even after 100 times dilution 
withwater which proves the system’s compatibility 
withexcess water. 
3.6 Refractive Index and Percent Transmittance
29
 
Refractive index and percent transmittance proved 
thetransparency of formulation. The refractive index of 
thesystem is measured by refractometer by placing drop 
ofsolution on slide and it compare with water (1.333). 
Thepercent transmittance of the system is measured 
atparticular wavelength using UV-
spectrophotometerkeeping distilled water as blank.If 
refractive index ofsystem is similar to the refractive 
index of water(1.333)and formulation have percent 
transmittance > 99 percent,then formulation have 
transparent nature. 
3.7 Electro conductivity Study 
The SEDD system contains ionic or non-ionic 
surfactant,oil, and water.so, this test is used to measure 
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theelectoconductive nature of system. The electro-
conductivity of resultant system is measured 
byelectoconductometer 
3.8 In Vitro Diffusion Study 
In vitro diffusion studies is performed to study the 
releasebehavior of formulation from liquid crystalline 
phasearound the droplet using dialysis technique. 
3.9 Drug content: 
Drug from pre-weighed SEDDS is extracted by 
dissolvingin suitable solvent. Drug content in the solvent 
extractwas analyzed by suitable analytical method 
against thestandard solvent solution of drug. 
3.10 Bioavailability study:
30
 
Based on the self emulsification properties, particle size 
data and stability of micro emulsion the formulation is 
selected for bioavailability studies. The in vivo study is 
performed to quantify the drug after administration of the 
formulation. Pharmacokinetic parameters of the 
maximum plasma concentration (Cmax) and the 
corresponding time (tmax) for the drug following oral 
administration are calculated. The relative 
Bioavailability of SEDDS formulation to the 
conventional tablet is calculated using the following 
Equation. 
Relative Bioavailability. 
(%) = (AUC test/AUC reference) X (Dose 
reference/Dose test). 
CONCLUSION 
The oral delivery of hydrophobic drugs can be made 
possible by SNEDDSs, which have been shown to 
substantially improve oral bioavailabilitywith future 
development of this technology. SEDDSs will continue 
to enable novelapplications in drug delivery and solve 
problems associated with the delivery of poorly soluble 
drugs .The nanosize of these formulations is responsible 
for facilitating enhancement of drug dissolution and 
absorption, owing to the large surface area. The lipidic 
nature of these systems allows delivery of drugs to the 
lymphatic system. The method employed in the 
investigation for screening of SNEDDS excipients 
helped in understanding the emulsification efficiency of 
various surfactants for selected oily phase. 
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